EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) connected Monday announced a backstage concern successful nationalist equity of 212 cardinal shares astatine $1.00 per share, representing a premium of 11.5% from the closing terms of the banal connected November 21, 2025.

The institution expects gross proceeds of astir $212 cardinal (funded successful a operation of $USD and USDT).

Enlivex volition usage the proceeds from the PIPE to instrumentality the archetypal RAIN prediction markets token treasury strategy, portion continuing its absorption connected the company's halfway concern operations.

RAIN is simply a afloat decentralized predictions and options protocol built connected the Arbitrum network. The protocol is afloat permissionless, allowing anyone to make and commercialized customized options connected immoderate market.

Market outcomes tin beryllium AI-resolved, and the level is governed by the RAIN token, which features a built-in, deflationary Buyback & Burn mechanism.

Designed to beryllium the "Uniswap" of prediction markets, RAIN is simply a protocol wherever anyone, from anywhere, tin make immoderate benignant of market, whether it's nationalist oregon private, successful immoderate language.

"We judge that pursuing the closing of this transaction and the implementation of the RAIN treasury strategy, Enlivex volition go the archetypal U.S.-traded nationalist institution to supply investors with an vulnerability to prediction markets", stated Shai Novik, Chairman of the Board of Directors of Enlivex.

Matteo Renzi, erstwhile Prime Minister of Italy, volition beryllium appointed to the Enlivex Board of Directors pursuing the closing of the backstage placement.

Enlivex has an operating concern focused connected late-stage objective improvement of Allocetra, a therapy designed to dainty the associated illness osteoarthritis.

Osteoarthritis is by acold the astir communal signifier of arthritis, affecting much than 32.5 cardinal Americans and much than 300 cardinal individuals worldwide.

Concurrently, Enlivex Therapeutics shared six-month efficacy information from the Phase 2a signifier of its randomized, multi-country Phase 1/2 Allocetra proceedings (ENX-CL-05-001) successful patients with mean to terrible genu osteoarthritis.

At 6 months, Allocetra continued to show important and durable simplification successful symptom and betterment successful relation crossed aggregate efficacy endpoints evaluated successful the aforesaid superior property radical (60+), arsenic compared to placebo.

Allocetra demonstrated a clinically meaningful betterment successful symptom and function, a composite endpoint which is expected to beryllium a cardinal endpoint successful the follow-up pivotal studies, reaching statistical value astatine 3 months astatine property 60+ (-26.8 points successful the Allocetra-treated radical versus -13.4 points successful the placebo group), and astatine 6 months astatine property 61+ (-27.8 points vs. -15.5 points).